| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | 5.76% | Wedbush | → $54 | Initiates Coverage On | → Neutral |
| 09/28/2023 | — | Berenberg | Initiates Coverage On | → Hold | |
| 09/20/2023 | 1.84% | Jefferies | → $52 | Initiates Coverage On | → Hold |
| 05/11/2023 | 5.76% | Wells Fargo | $52 → $54 | Maintains | Equal-Weight |
| 03/29/2023 | -2.08% | Credit Suisse | $55 → $50 | Maintains | Neutral |
| 12/09/2022 | 13.59% | Credit Suisse | $47 → $58 | Upgrades | Underperform → Neutral |
| 09/26/2022 | 19.47% | Truist Securities | $64 → $61 | Maintains | Hold |
| 06/21/2022 | 21.43% | BMO Capital | → $62 | Downgrades | Outperform → Market Perform |
| 04/19/2022 | 19.47% | BMO Capital | $63 → $61 | Maintains | Outperform |
| 02/01/2022 | -0.12% | Credit Suisse | → $51 | Initiates Coverage On | → Underperform |
| 01/07/2022 | 33.18% | BMO Capital | → $68 | Upgrades | Market Perform → Outperform |
| 07/23/2021 | 41.01% | Wells Fargo | $74 → $72 | Maintains | Equal-Weight |
| 06/18/2021 | 39.05% | BMO Capital | → $71 | Upgrades | Underperform → Market Perform |
| 03/30/2021 | 50.8% | Capital One | → $77 | Downgrades | Overweight → Equal-Weight |
| 01/13/2021 | 7.72% | Mizuho | → $55 | Downgrades | Neutral → Underperform |
| 01/08/2021 | — | BMO Capital | Downgrades | Market Perform → Underperform | |
| 12/14/2020 | — | Keybanc | Upgrades | Underweight → Sector Weight | |
| 09/02/2020 | 23.38% | Stifel | → $63 | Reinstates | → Hold |
| 06/24/2020 | 25.34% | SunTrust Robinson Humphrey | $61 → $64 | Maintains | Hold |
| 06/17/2020 | 29.26% | Wells Fargo | $54 → $66 | Maintains | Equal-Weight |
| 06/08/2020 | — | JMP Securities | Reinstates | → Market Perform | |
| 05/22/2020 | 7.72% | Mizuho | $60 → $55 | Downgrades | Buy → Neutral |
| 05/14/2020 | -21.66% | Keybanc | $43 → $40 | Maintains | Underweight |
| 04/23/2020 | 19.47% | SunTrust Robinson Humphrey | $77 → $61 | Maintains | Hold |
| 04/21/2020 | -15.79% | Keybanc | $65 → $43 | Maintains | Underweight |
| 03/26/2020 | -0.12% | Wells Fargo | $82 → $51 | Maintains | Equal-Weight |
| 02/05/2020 | — | Berenberg | Initiates Coverage On | → Buy | |
| 01/07/2020 | 60.6% | BMO Capital | → $82 | Upgrades | Underperform → Market Perform |
| 12/20/2019 | 86.06% | Mizuho | → $95 | Assumes | → Buy |
| 02/20/2019 | — | BMO Capital | Downgrades | Market Perform → Underperform |
What is the target price for National Health Investors (NHI)?
The latest price target for National Health Investors (NYSE: NHI) was reported by Wedbush on October 3, 2023. The analyst firm set a price target for $54.00 expecting NHI to rise to within 12 months (a possible 5.76% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for National Health Investors (NHI)?
The latest analyst rating for National Health Investors (NYSE: NHI) was provided by Wedbush, and National Health Investors initiated their neutral rating.
When is the next analyst rating going to be posted or updated for National Health Investors (NHI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of National Health Investors, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for National Health Investors was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
Is the Analyst Rating National Health Investors (NHI) correct?
While ratings are subjective and will change, the latest National Health Investors (NHI) rating was a initiated with a price target of $0.00 to $54.00. The current price National Health Investors (NHI) is trading at is $51.06, which is within the analyst's predicted range.